APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Hepatitis B Immunoglobulin (HBIG)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human Hepatitis B Immunoglobulin (HBIG) Market Outlook and Growth Opportunities 2026

26 December 2025192 pages

Choose your research edition.

Industry ResearchHuman Hepatitis B Immunoglobulin (HBIG) Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Hepatitis B Immunoglobulin (HBIG) Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Human Hepatitis B Immunoglobulin (HBIG) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Hepatitis B Immunoglobulin (HBIG) Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Hepatitis B Immunoglobulin (HBIG) Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Human Hepatitis B Immunoglobulin (HBIG) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human Hepatitis B Immunoglobulin (HBIG) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Hepatitis B Immunoglobulin (HBIG) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Hepatitis B Immunoglobulin (HBIG) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human Hepatitis B Immunoglobulin (HBIG) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human Hepatitis B Immunoglobulin (HBIG) market include Boya Bio-pharmaceutical, CSL, Grifols, Octapharma, Baxter, Bayer, Tiantan Biologic, Shuanglin Bio-pharmacy and Hualan Biological, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Human Hepatitis B Immunoglobulin (HBIG) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Hepatitis B Immunoglobulin (HBIG) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Hepatitis B Immunoglobulin (HBIG) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Hepatitis B Immunoglobulin (HBIG) market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Hepatitis B Immunoglobulin (HBIG) Segment by Company

Boya Bio-pharmaceutical

CSL

Grifols

Octapharma

Baxter

Bayer

Tiantan Biologic

Shuanglin Bio-pharmacy

Hualan Biological

Shanghai RAAS

Sichuan Yuanda Shuyang

China Biologic

Shanghai Institute of Biological

Human Hepatitis B Immunoglobulin (HBIG) Segment by Type

100IU/Bottle Human Hepatitis B Immunoglobulin

200IU/Bottle Human Hepatitis B Immunoglobulin

400IU/Bottle Human Hepatitis B Immunoglobulin

Human Hepatitis B Immunoglobulin (HBIG) Segment by Application

Close Contacts of Patients with Hepatitis B and Hepatitis B Virus Carriers

Positive Infants Born to Mothers With Hepatitis B Surface Antigen(HBsAg)

Unexpected Crowd of Hepatitis B Infection

Human Hepatitis B Immunoglobulin (HBIG) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Human Hepatitis B Immunoglobulin (HBIG) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Human Hepatitis B Immunoglobulin (HBIG) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Hepatitis B Immunoglobulin (HBIG) significant trends, drivers, influence factors in global and regions.

6. To analyze Human Hepatitis B Immunoglobulin (HBIG) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Hepatitis B Immunoglobulin (HBIG) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Hepatitis B Immunoglobulin (HBIG) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Hepatitis B Immunoglobulin (HBIG).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Hepatitis B Immunoglobulin (HBIG) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Hepatitis B Immunoglobulin (HBIG) industry.

Chapter 3: Detailed analysis of Human Hepatitis B Immunoglobulin (HBIG) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Human Hepatitis B Immunoglobulin (HBIG) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Human Hepatitis B Immunoglobulin (HBIG) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Hepatitis B Immunoglobulin (HBIG) Industry Trends Table 2. Human Hepatitis B Immunoglobulin (HBIG) Industry Drivers Table 3. Human Hepatitis B Immunoglobulin (HBIG) Industry Opportunities and Challenges Table 4. Human Hepatitis B Immunoglobulin (HBIG) Industry Restraints Table 5. Global Human Hepatitis B Immunoglobulin (HBIG) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Hepatitis B Immunoglobulin (HBIG) Revenue Share by Company (2021-2026) Table 7. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume Share by Company (2021-2026) Table 9. Global Human Hepatitis B Immunoglobulin (HBIG) Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Human Hepatitis B Immunoglobulin (HBIG) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Human Hepatitis B Immunoglobulin (HBIG) Key Company Manufacturing Base & Headquarters Table 12. Global Human Hepatitis B Immunoglobulin (HBIG) Company, Product Type & Application Table 13. Global Human Hepatitis B Immunoglobulin (HBIG) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Hepatitis B Immunoglobulin (HBIG) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 100IU/Bottle Human Hepatitis B Immunoglobulin Table 18. Significant Companies of 200IU/Bottle Human Hepatitis B Immunoglobulin Table 19. Significant Companies of 400IU/Bottle Human Hepatitis B Immunoglobulin Table 20. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume Share by Type (2021-2026) Table 24. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume Share by Type (2027-2032) Table 25. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type (2021-2026) Table 29. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Close Contacts of Patients with Hepatitis B and Hepatitis B Virus Carriers Table 31. Significant Companies of Positive Infants Born to Mothers With Hepatitis B Surface Antigen(HBsAg) Table 32. Significant Companies of Unexpected Crowd of Hepatitis B Infection Table 33. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume Share by Application (2021-2026) Table 37. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume Share by Application (2027-2032) Table 38. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application (2021-2026) Table 42. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application (2027-2032) Table 43. Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Region (2021-2026) & (K Units) Table 45. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Market Share by Region (2021-2026) Table 46. Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Region (2027-2032) & (K Units) Table 47. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Market Share by Region (2027-2032) Table 48. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Region (2021-2026) Table 51. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Region (2027-2032) Table 53. Global Human Hepatitis B Immunoglobulin (HBIG) Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Human Hepatitis B Immunoglobulin (HBIG) Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Country (2021-2026) & (K Units) Table 58. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Market Share by Country (2021-2026) Table 59. Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Country (2027-2032) & (K Units) Table 60. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Market Share by Country (2027-2032) Table 61. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value Market Share by Country (2021-2026) Table 63. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value Market Share by Country (2027-2032) Table 65. Boya Bio-pharmaceutical Company Information Table 66. Boya Bio-pharmaceutical Business Overview Table 67. Boya Bio-pharmaceutical Human Hepatitis B Immunoglobulin (HBIG) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Boya Bio-pharmaceutical Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio Table 69. Boya Bio-pharmaceutical Recent Development Table 70. CSL Company Information Table 71. CSL Business Overview Table 72. CSL Human Hepatitis B Immunoglobulin (HBIG) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. CSL Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio Table 74. CSL Recent Development Table 75. Grifols Company Information Table 76. Grifols Business Overview Table 77. Grifols Human Hepatitis B Immunoglobulin (HBIG) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Grifols Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio Table 79. Grifols Recent Development Table 80. Octapharma Company Information Table 81. Octapharma Business Overview Table 82. Octapharma Human Hepatitis B Immunoglobulin (HBIG) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Octapharma Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio Table 84. Octapharma Recent Development Table 85. Baxter Company Information Table 86. Baxter Business Overview Table 87. Baxter Human Hepatitis B Immunoglobulin (HBIG) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Baxter Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio Table 89. Baxter Recent Development Table 90. Bayer Company Information Table 91. Bayer Business Overview Table 92. Bayer Human Hepatitis B Immunoglobulin (HBIG) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Bayer Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio Table 94. Bayer Recent Development Table 95. Tiantan Biologic Company Information Table 96. Tiantan Biologic Business Overview Table 97. Tiantan Biologic Human Hepatitis B Immunoglobulin (HBIG) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Tiantan Biologic Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio Table 99. Tiantan Biologic Recent Development Table 100. Shuanglin Bio-pharmacy Company Information Table 101. Shuanglin Bio-pharmacy Business Overview Table 102. Shuanglin Bio-pharmacy Human Hepatitis B Immunoglobulin (HBIG) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Shuanglin Bio-pharmacy Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio Table 104. Shuanglin Bio-pharmacy Recent Development Table 105. Hualan Biological Company Information Table 106. Hualan Biological Business Overview Table 107. Hualan Biological Human Hepatitis B Immunoglobulin (HBIG) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Hualan Biological Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio Table 109. Hualan Biological Recent Development Table 110. Shanghai RAAS Company Information Table 111. Shanghai RAAS Business Overview Table 112. Shanghai RAAS Human Hepatitis B Immunoglobulin (HBIG) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Shanghai RAAS Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio Table 114. Shanghai RAAS Recent Development Table 115. Sichuan Yuanda Shuyang Company Information Table 116. Sichuan Yuanda Shuyang Business Overview Table 117. Sichuan Yuanda Shuyang Human Hepatitis B Immunoglobulin (HBIG) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Sichuan Yuanda Shuyang Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio Table 119. Sichuan Yuanda Shuyang Recent Development Table 120. China Biologic Company Information Table 121. China Biologic Business Overview Table 122. China Biologic Human Hepatitis B Immunoglobulin (HBIG) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. China Biologic Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio Table 124. China Biologic Recent Development Table 125. Shanghai Institute of Biological Company Information Table 126. Shanghai Institute of Biological Business Overview Table 127. Shanghai Institute of Biological Human Hepatitis B Immunoglobulin (HBIG) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Shanghai Institute of Biological Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio Table 129. Shanghai Institute of Biological Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Human Hepatitis B Immunoglobulin (HBIG) Distributors List Table 133. Human Hepatitis B Immunoglobulin (HBIG) Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Human Hepatitis B Immunoglobulin (HBIG) Product Image Figure 2. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Human Hepatitis B Immunoglobulin (HBIG) Sales (2021-2032) & (K Units) Figure 5. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Human Hepatitis B Immunoglobulin (HBIG) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 100IU/Bottle Human Hepatitis B Immunoglobulin Image Figure 10. 200IU/Bottle Human Hepatitis B Immunoglobulin Image Figure 11. 400IU/Bottle Human Hepatitis B Immunoglobulin Image Figure 12. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume Share by Type (2021-2032) Figure 15. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type (2021-2032) Figure 18. Close Contacts of Patients with Hepatitis B and Hepatitis B Virus Carriers Image Figure 19. Positive Infants Born to Mothers With Hepatitis B Surface Antigen(HBsAg) Image Figure 20. Unexpected Crowd of Hepatitis B Infection Image Figure 21. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume Share by Application (2021-2032) Figure 24. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application (2021-2032) Figure 27. Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Human Hepatitis B Immunoglobulin (HBIG) Sales Value (2021-2032) & (US$ Million) Figure 32. North America Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Human Hepatitis B Immunoglobulin (HBIG) Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Human Hepatitis B Immunoglobulin (HBIG) Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Human Hepatitis B Immunoglobulin (HBIG) Sales Value (2021-2032) & (US$ Million) Figure 38. South America Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Human Hepatitis B Immunoglobulin (HBIG) Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Human Hepatitis B Immunoglobulin (HBIG) Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Human Hepatitis B Immunoglobulin (HBIG) Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 100IU/Bottle Human Hepatitis B Immunoglobulin
  • 200IU/Bottle Human Hepatitis B Immunoglobulin
  • 400IU/Bottle Human Hepatitis B Immunoglobulin
Applications
  • Close Contacts of Patients with Hepatitis B and Hepatitis B Virus Carriers
  • Positive Infants Born to Mothers With Hepatitis B Surface Antigen(HBsAg)
  • Unexpected Crowd of Hepatitis B Infection
Companies covered
  • Boya Bio-pharmaceutical
  • CSL
  • Grifols
  • Octapharma
  • Baxter
  • Bayer
  • Tiantan Biologic
  • Shuanglin Bio-pharmacy
  • Hualan Biological
  • Shanghai RAAS
  • Sichuan Yuanda Shuyang
  • China Biologic
  • Shanghai Institute of Biological

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value (2021-2032)
  4. 1.2.2 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume (2021-2032)
  5. 1.2.3 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Human Hepatitis B Immunoglobulin (HBIG) Market Dynamics
  1. 2.1 Human Hepatitis B Immunoglobulin (HBIG) Industry Trends
  2. 2.2 Human Hepatitis B Immunoglobulin (HBIG) Industry Drivers
  3. 2.3 Human Hepatitis B Immunoglobulin (HBIG) Industry Opportunities and Challenges
  4. 2.4 Human Hepatitis B Immunoglobulin (HBIG) Industry Restraints
3 Human Hepatitis B Immunoglobulin (HBIG) Market by Company
  1. 3.1 Global Human Hepatitis B Immunoglobulin (HBIG) Company Revenue Ranking in 2025
  2. 3.2 Global Human Hepatitis B Immunoglobulin (HBIG) Revenue by Company (2021-2026)
  3. 3.3 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume by Company (2021-2026)
  4. 3.4 Global Human Hepatitis B Immunoglobulin (HBIG) Average Price by Company (2021-2026)
  5. 3.5 Global Human Hepatitis B Immunoglobulin (HBIG) Company Ranking (2024-2026)
  6. 3.6 Global Human Hepatitis B Immunoglobulin (HBIG) Company Manufacturing Base and Headquarters
  7. 3.7 Global Human Hepatitis B Immunoglobulin (HBIG) Company Product Type and Application
  8. 3.8 Global Human Hepatitis B Immunoglobulin (HBIG) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Human Hepatitis B Immunoglobulin (HBIG) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Human Hepatitis B Immunoglobulin (HBIG) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Human Hepatitis B Immunoglobulin (HBIG) Market by Type
  1. 4.1 Human Hepatitis B Immunoglobulin (HBIG) Type Introduction
  2. 4.1.1 100IU/Bottle Human Hepatitis B Immunoglobulin
  3. 4.1.2 200IU/Bottle Human Hepatitis B Immunoglobulin
  4. 4.1.3 400IU/Bottle Human Hepatitis B Immunoglobulin
  5. 4.2 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume by Type
  6. 4.2.1 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Type
  10. 4.3.1 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Type (2021-2032)
  12. 4.3.3 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type (2021-2032)
5 Human Hepatitis B Immunoglobulin (HBIG) Market by Application
  1. 5.1 Human Hepatitis B Immunoglobulin (HBIG) Application Introduction
  2. 5.1.1 Close Contacts of Patients with Hepatitis B and Hepatitis B Virus Carriers
  3. 5.1.2 Positive Infants Born to Mothers With Hepatitis B Surface Antigen(HBsAg)
  4. 5.1.3 Unexpected Crowd of Hepatitis B Infection
  5. 5.2 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume by Application
  6. 5.2.1 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Application
  10. 5.3.1 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Application (2021-2032)
  12. 5.3.3 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application (2021-2032)
6 Human Hepatitis B Immunoglobulin (HBIG) Regional Sales and Value Analysis
  1. 6.1 Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Region (2021-2032)
  3. 6.2.1 Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Region: 2021-2026
  4. 6.2.2 Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Region (2027-2032)
  5. 6.3 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Region (2027-2032)
  9. 6.5 Global Human Hepatitis B Immunoglobulin (HBIG) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Human Hepatitis B Immunoglobulin (HBIG) Sales Value (2021-2032)
  12. 6.6.2 North America Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Human Hepatitis B Immunoglobulin (HBIG) Sales Value (2021-2032)
  15. 6.7.2 Europe Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Human Hepatitis B Immunoglobulin (HBIG) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Human Hepatitis B Immunoglobulin (HBIG) Sales Value (2021-2032)
  21. 6.9.2 South America Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Human Hepatitis B Immunoglobulin (HBIG) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Country, 2025 VS 2032
7 Human Hepatitis B Immunoglobulin (HBIG) Country-level Sales and Value Analysis
  1. 7.1 Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Country (2021-2032)
  4. 7.3.1 Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Country (2021-2026)
  5. 7.3.2 Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Country (2027-2032)
  6. 7.4 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Human Hepatitis B Immunoglobulin (HBIG) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Human Hepatitis B Immunoglobulin (HBIG) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Boya Bio-pharmaceutical
  2. 8.1.1 Boya Bio-pharmaceutical Company Information
  3. 8.1.2 Boya Bio-pharmaceutical Business Overview
  4. 8.1.3 Boya Bio-pharmaceutical Human Hepatitis B Immunoglobulin (HBIG) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Boya Bio-pharmaceutical Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
  6. 8.1.5 Boya Bio-pharmaceutical Recent Developments
  7. 8.2 CSL
  8. 8.2.1 CSL Company Information
  9. 8.2.2 CSL Business Overview
  10. 8.2.3 CSL Human Hepatitis B Immunoglobulin (HBIG) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 CSL Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
  12. 8.2.5 CSL Recent Developments
  13. 8.3 Grifols
  14. 8.3.1 Grifols Company Information
  15. 8.3.2 Grifols Business Overview
  16. 8.3.3 Grifols Human Hepatitis B Immunoglobulin (HBIG) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Grifols Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
  18. 8.3.5 Grifols Recent Developments
  19. 8.4 Octapharma
  20. 8.4.1 Octapharma Company Information
  21. 8.4.2 Octapharma Business Overview
  22. 8.4.3 Octapharma Human Hepatitis B Immunoglobulin (HBIG) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Octapharma Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
  24. 8.4.5 Octapharma Recent Developments
  25. 8.5 Baxter
  26. 8.5.1 Baxter Company Information
  27. 8.5.2 Baxter Business Overview
  28. 8.5.3 Baxter Human Hepatitis B Immunoglobulin (HBIG) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Baxter Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
  30. 8.5.5 Baxter Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Human Hepatitis B Immunoglobulin (HBIG) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 Tiantan Biologic
  38. 8.7.1 Tiantan Biologic Company Information
  39. 8.7.2 Tiantan Biologic Business Overview
  40. 8.7.3 Tiantan Biologic Human Hepatitis B Immunoglobulin (HBIG) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Tiantan Biologic Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
  42. 8.7.5 Tiantan Biologic Recent Developments
  43. 8.8 Shuanglin Bio-pharmacy
  44. 8.8.1 Shuanglin Bio-pharmacy Company Information
  45. 8.8.2 Shuanglin Bio-pharmacy Business Overview
  46. 8.8.3 Shuanglin Bio-pharmacy Human Hepatitis B Immunoglobulin (HBIG) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Shuanglin Bio-pharmacy Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
  48. 8.8.5 Shuanglin Bio-pharmacy Recent Developments
  49. 8.9 Hualan Biological
  50. 8.9.1 Hualan Biological Company Information
  51. 8.9.2 Hualan Biological Business Overview
  52. 8.9.3 Hualan Biological Human Hepatitis B Immunoglobulin (HBIG) Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Hualan Biological Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
  54. 8.9.5 Hualan Biological Recent Developments
  55. 8.10 Shanghai RAAS
  56. 8.10.1 Shanghai RAAS Company Information
  57. 8.10.2 Shanghai RAAS Business Overview
  58. 8.10.3 Shanghai RAAS Human Hepatitis B Immunoglobulin (HBIG) Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Shanghai RAAS Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
  60. 8.10.5 Shanghai RAAS Recent Developments
  61. 8.11 Sichuan Yuanda Shuyang
  62. 8.11.1 Sichuan Yuanda Shuyang Company Information
  63. 8.11.2 Sichuan Yuanda Shuyang Business Overview
  64. 8.11.3 Sichuan Yuanda Shuyang Human Hepatitis B Immunoglobulin (HBIG) Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Sichuan Yuanda Shuyang Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
  66. 8.11.5 Sichuan Yuanda Shuyang Recent Developments
  67. 8.12 China Biologic
  68. 8.12.1 China Biologic Company Information
  69. 8.12.2 China Biologic Business Overview
  70. 8.12.3 China Biologic Human Hepatitis B Immunoglobulin (HBIG) Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 China Biologic Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
  72. 8.12.5 China Biologic Recent Developments
  73. 8.13 Shanghai Institute of Biological
  74. 8.13.1 Shanghai Institute of Biological Company Information
  75. 8.13.2 Shanghai Institute of Biological Business Overview
  76. 8.13.3 Shanghai Institute of Biological Human Hepatitis B Immunoglobulin (HBIG) Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Shanghai Institute of Biological Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
  78. 8.13.5 Shanghai Institute of Biological Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Hepatitis B Immunoglobulin (HBIG) Value Chain Analysis
  2. 9.1.1 Human Hepatitis B Immunoglobulin (HBIG) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Hepatitis B Immunoglobulin (HBIG) Sales Mode & Process
  6. 9.2 Human Hepatitis B Immunoglobulin (HBIG) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Hepatitis B Immunoglobulin (HBIG) Distributors
  9. 9.2.3 Human Hepatitis B Immunoglobulin (HBIG) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst